摘要
目的:探讨中国汉族人群纤溶酶原激活物抑制剂PAI-1启动子4G/5G基因多态性与静脉血栓栓塞症(VTE)发病的相关性。方法:采用病例-对照研究,收集南京鼓楼医院2016年1月~2018年3月VTE患者160例及正常人群160例,应用聚合酶链反应测定PAI-1启动子区域的4G/5G的多态性。结果:PAI-1基因4G/5G三种基因型4G/4G型、4G/5G型、5G/5G型在VTE组的分布频率为42.50%、35.00%、22.50%,对照组分布频率为17.50%、43.12%、39.38%,VTE组与对照组4G/4G基因型分布差异具有统计学意义(P<0.05);通过非条件Logistic回归模型校正后,PAI-1 4G/4G基因型(OR=3.398,95%CI=2.025~5.702,P=0.000)、吸烟(OR=1.447,95%CI=1.022~2.049,P=0.037)是VTE的独立危险因素。结论:VTE组PAI-1 4G/4G基因型频率较正常人群高,证实了4G/4G基因型与静脉血栓栓塞发病有相关性,且为独立危险因素。
Objective：In this study,the distribution of genotypes and frequency of alleles of the 4G/5G polymorphism of PAI-1 gene in Chinese patients with venous thrombosis were investigated for their roles in development of venous thromboembolism.Methods：A case-control study was conducted in the Nanjing Drum Tower Hospital.A total of 160 VTE patients and 160 healthy controls were studied for the PAI-14G/5G polymorphism by allele-specific PCR from January 2016 to March 2018.Results：The frequency distribution of 4G/4G,4G/5G and 5G/5G genotypes were 42.50%,35.00% and 22.50% in the VTE group,and 17.50%,43.12% and 39.38% in the control group,respectively.The difference of PAI-1 4G/4G genotype distribution between the VTE group and the control group was statistically significant（P〈0.05）;Corrected by unconditional logistic regression model,4G/4G was associated with VTE risk（OR=3.398,95%CI=2.025~5.702,P=0.000）and smoking（OR=1.447,95% CI=1.022~2.049,P=0.037）was an independent risk factor for VTE.Conclusions：PAI-1 4G/4G is an independent strong risk factor for venous thrombosis in Chinese patients and should be included in laboratory testing panel of thrombophilia.
作者
徐航
王璐
王宝彦
李丹滢
雷署丰
XU Hang1,2,WANG Lu3,WANG Baoyan2,LI Danying2,LEI Shufeng1(1School of Public Health, Medical College of Soochow University, Suzhou, Jiangsu Province 215123, Chinca; 2Department of Pharmacy in the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu Province 210008, China; 3College of Basic Medicine and Clinical Pharmacy in China Pharmaceutical University, Nanjing,Jiangsu Province 210009, Chin)
出处
《药学与临床研究》
2018年第4期261-264,共4页
Pharmaceutical and Clinical Research
基金
南京市医学科技发展资金资助(QRX17060)
江苏省药学会-Shire生物药学基金(S201606)
